Merus N.V. (MRUS)

NL — Healthcare Sector
Peers: ANEB  ADAG  ACRV  ANAB  MLYS  CRNX  INBX  LYEL  KRON  KURA  PTGX  REPL  CERE  PCVX  LRMR  SNDX  STRO 

Automate Your Wheel Strategy on MRUS

With Tiblio's Option Bot, you can configure your own wheel strategy including MRUS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol MRUS
  • Rev/Share 0.793
  • Book/Share 8.6372
  • PB 6.4917
  • Debt/Equity 0.003
  • CurrentRatio 5.8597
  • ROIC -0.4832

 

  • MktCap 3880806552.0
  • FreeCF/Share -3.4728
  • PFCF -16.1913
  • PE -13.9531
  • Debt/Assets 0.0024
  • DivYield 0
  • ROE -0.4118

 

  • Rating C-
  • Score 1
  • Recommendation Strong Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 1
  • D/E Score 4

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation MRUS Piper Sandler -- Overweight -- $84 Feb. 13, 2025
Initiation MRUS Wells Fargo -- Overweight -- $91 Feb. 7, 2025

News

Merus' Petosemtamab with Pembrolizumab Interim Data Demonstrates Robust Efficacy and Durability in 1L PD-L1+ r/m HNSCC
MRUS
Published: May 22, 2025 by: GlobeNewsWire
Sentiment: Neutral

- 63% response rate observed among 43 evaluable patients - 79% overall survival rate at 12-months; 9 months median progression-free survival - Conference Call on Thursday, May 22 at 5:30 p.m. ET UTRECHT, The Netherlands and CAMBRIDGE, Mass.

Read More
image for news Merus' Petosemtamab with Pembrolizumab Interim Data Demonstrates Robust Efficacy and Durability in 1L PD-L1+ r/m HNSCC
Merus N.V. (MRUS) Reports Q1 Loss, Tops Revenue Estimates
MRUS
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Negative

Merus N.V. (MRUS) came out with a quarterly loss of $1.40 per share versus the Zacks Consensus Estimate of a loss of $1.16. This compares to loss of $0.59 per share a year ago.

Read More
image for news Merus N.V. (MRUS) Reports Q1 Loss, Tops Revenue Estimates
Earnings Preview: Merus N.V. (MRUS) Q1 Earnings Expected to Decline
MRUS
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Negative

Merus (MRUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Read More
image for news Earnings Preview: Merus N.V. (MRUS) Q1 Earnings Expected to Decline
Merus Announces Abstract Accepted for Presentation at the 2025 ASCO® Annual Meeting
MRUS
Published: April 23, 2025 by: GlobeNewsWire
Sentiment: Neutral

- Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC interim clinical data selected for poster presentation

Read More
image for news Merus Announces Abstract Accepted for Presentation at the 2025 ASCO® Annual Meeting
Merus to Present at Upcoming Investor Conferences
MRUS
Published: February 25, 2025 by: GlobeNewsWire
Sentiment: Neutral

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Merus N.V.

Read More
image for news Merus to Present at Upcoming Investor Conferences
Petosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinoma
MRUS
Published: February 18, 2025 by: GlobeNewsWire
Sentiment: Neutral

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Merus N.V.

Read More
image for news Petosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinoma
Merus to Present at Citi's 2025 Virtual Oncology Leadership Summit
MRUS
Published: February 13, 2025 by: GlobeNewsWire
Sentiment: Neutral

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Merus N.V.

Read More
image for news Merus to Present at Citi's 2025 Virtual Oncology Leadership Summit

About Merus N.V. (MRUS)

  • IPO Date 2016-05-19
  • Website https://www.merus.nl
  • Industry Biotechnology
  • CEO Dr. Sven Ante Lundberg M.D.
  • Employees 260

Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.